A Workflow to Quantitatively Determine Age-Related Macular Degeneration Lesion-Specific Variations in Fundus Autofluorescence
May 26th, 2023
This research describes a workflow to determine and compare autofluorescence levels from individual regions of interest (e.g., drusen and subretinal drusenoid deposits in age-related macular degeneration [AMD]) while accounting for varying autofluorescence levels throughout the fundus.
So far, quantitative autofluorescence or QAF, analysis was limited to prefabricated grids analyzing global autofluorescence of the posterior pole of the eye. Our protocol allows the measurement and comparison of autofluorescence intensities of specific regions of interest. QAF revealed reduced autofluorescence intensities in age-related macular degeneration.
As a matter of fact, this important finding contradicted the historical view of pathological lipofuscin accumulations in the AMD. Today, the clinical findings can nicely be confirmed by new histological data on the retinal pigment epithelium at the cellular level. The characteristic autofluorescence levels of the ocular fundus display strong regional differences.
There seems to be a strong relationship between autofluorescence and rod photoreceptor density. For an accurate comparison of autofluorescence, one needs to account for regional differences, which is challenging. We could show for the first time the typical AMD lesions like drusen show further reduced autofluorescence intensities in addition to the generally reduced autofluorescence levels in these patients.
We are currently focusing on spectral analysis of the emitted light from fluorophores from the retinal pigment epithelium in both in vivo and ex vivo settings. With this approach, we hope to get better information on the physiology and pathophysiology of photoreceptors and the retinal pigment epithelium in healthy and deceased eyes.
Overview
This research describes a workflow to determine and compare autofluorescence levels from individual regions of interest in age-related macular degeneration (AMD). The study highlights the importance of accounting for varying autofluorescence levels throughout the fundus.
Key Study Components
Area of Science
- Neuroscience
- Ophthalmology
- Pathophysiology
Background
- Quantitative autofluorescence (QAF) analysis was previously limited to global assessments.
- This study introduces a protocol for measuring specific regions of interest.
- Findings reveal reduced autofluorescence intensities in AMD, challenging historical views.
- Strong regional differences in autofluorescence levels are observed.
Purpose of Study
- To develop a method for comparing autofluorescence intensities in AMD.
- To investigate the relationship between autofluorescence and rod photoreceptor density.
- To provide insights into the physiology and pathophysiology of retinal structures.
Methods Used
- Quantitative autofluorescence analysis of specific retinal regions.
- Comparison of autofluorescence levels in AMD lesions like drusen.
- Spectral analysis of emitted light from retinal pigment epithelium.
- In vivo and ex vivo settings for comprehensive assessment.
Main Results
- Reduced autofluorescence intensities were confirmed in AMD.
- AMD lesions exhibited further reduced autofluorescence levels.
- New histological data supports clinical findings.
- Regional differences in autofluorescence levels were established.
Conclusions
- The study provides a novel approach to assess autofluorescence in AMD.
- Findings may influence future diagnostic and therapeutic strategies.
- Understanding regional differences is crucial for accurate assessments.
Frequently Asked Questions
Executive Industry Relevance
Quantitative fundus autofluorescence (QAF) mapping enables precise, lesion-specific measurement of retinal pigment epithelium (RPE) function in age-related macular degeneration (AMD), addressing a critical gap in disease-relevant phenotyping. This workflow supports predictive confidence in early discovery and translational research by providing standardized, quantitative outputs for lesion characterization. Integrating multimodal imaging and advanced analytics, the approach enhances portfolio decision-making for ocular disease programs.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables quantitative interrogation of RPE dysfunction at lesion-specific resolution in AMD.
- Supports mechanistic de-risking by correlating autofluorescence with photoreceptor and RPE pathology.
- Facilitates functional target validation through standardized, reproducible imaging metrics.
Screening & Assay Development
- Prepares validated, quantitative imaging endpoints for downstream screening of therapeutic candidates.
- Standardizes lesion marking and measurement, improving reproducibility across studies.
- Generates scalable, quantitative data sets for comparative analysis of compound effects on retinal lesions.
Translational & Preclinical Research
- Aligns imaging biomarkers with disease-relevant endpoints for preclinical and clinical continuity.
- Enables risk-adjusted advancement by quantifying lesion-specific changes in response to interventions.
- Supports translational biomarker development for AMD progression and therapeutic response.
Pipeline & Workflow Integration
This workflow integrates from early discovery through translational research, providing quantitative imaging outputs for hypothesis testing, target validation, and preclinical assessment in AMD.
- Discovery Biology: Quantitative lesion mapping clarifies RPE and photoreceptor pathway involvement in AMD.
- Screening: Standardized QAF and OCT-based endpoints enable reproducible compound evaluation.
- Analytics: Z-score and intensity measurements provide robust, comparative readouts for lesion analysis.
- Translational Research: Normative QAF maps and lesion-specific metrics support biomarker alignment across preclinical and clinical studies.
- Enterprise Reuse: The workflow and plug-ins are adaptable for broader retinal disease research and cross-study standardization.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in AMD lesion assessment.
- Operational Value: Delivers standardized, reproducible, and scalable imaging analytics for cross-functional teams.
- Strategic Value: Improves go/no-go decisions and capital allocation by providing quantitative, disease-relevant endpoints.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of ocular disease assets.
Implementation Considerations
- Requires expertise in multimodal retinal imaging and quantitative image analysis.
- Needs access to confocal scanning laser ophthalmoscopy, SD-OCT, and FIJI-based analytical infrastructure.
- Demands cross-team standardization of lesion marking and image registration protocols.
- Adaptable to various AMD lesion types and potentially other retinal diseases with similar imaging characteristics.
- Dependent on high-quality imaging data and robust normative map generation for accurate z-score calculation.
